Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases
Pharmaceutics · 07.04.2025 · 17 (4) · 479
DOI: 10.3390/pharmaceutics17040479 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 07.04.2025. Verfasst von Xuying Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 200 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Aier Ophthalmology-Sichuan University Scientific Research Fund Project, the Clinical Research Incubation Project, West China Hospital, Sichuan University, the Sichuan Provincial Science and Technology Department Key R&D Projects.
Abstract (Originalsprache)
Matrix metalloproteinase-9 (MMP-9) is implicated in tumor progression and vascular diseases, contributing to angiogenesis, metastasis, and extracellular matrix degradation. This review comprehensively examines the relationship between MMP-9 and these pathologies, exploring the underlying molecular mechanisms and signaling pathways involved. Specifically, we discuss the contribution of MMP-9 to tumor epithelial–mesenchymal transition, angiogenesis, and metastasis, as well as its involvement in a spectrum of vascular diseases, including macrovascular, cerebrovascular, and ocular vascular diseases. This review focuses on recent advances in MMP-9-targeted nanomedicine strategies, highlighting the design and application of responsive nanoparticles for enhanced drug delivery. These nanotherapeutic strategies leverage MMP-9 overexpression to achieve targeted drug release, improved tumor penetration, and reduced systemic toxicity. We explore various nanoparticle platforms, such as liposomes and polymer nanoparticles, and discuss their mechanisms of action, including degradation, drug release, and targeting specificity. Finally, we address the challenges posed by the heterogeneity of MMP-9 expression and their implications for personalized therapies. Ultimately, this review underscores the diagnostic and therapeutic potential of MMP-9-targeted nanomedicines against tumors and vascular diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, China.
ORCID-Profile: Zhuping Xu
Förderung
- the Aier Ophthalmology-Sichuan University Scientific Research Fund Project
- the Clinical Research Incubation Project, West China Hospital, Sichuan University
- the Sichuan Provincial Science and Technology Department Key R&D Projects
- the Aier Ophthalmology–Sichuan University Scientific Research Fund Project
- the Sichuan Provincial Science and Technology Department Key R&D Projects
Zitieren
APA
Li, X., & Xu, Z. (2025). Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases. Pharmaceutics, 17(4), 479. https://doi.org/10.3390/pharmaceutics17040479
Vancouver
Li X, Xu Z. Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases. Pharmaceutics. 2025;17(4):479. doi:10.3390/pharmaceutics17040479
BibTeX
@article{Li2025,
author = {Li, Xuying and Xu, Zhuping},
title = {Applications of Matrix Metalloproteinase-9-Related Nanomedicines in Tumors and Vascular Diseases},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {4},
pages = {479},
doi = {10.3390/pharmaceutics17040479}
}
EUVIMED